 0000895345-11-000132.txt : 20110415 0000895345-11-000132.hdr.sgml : 20110415 20110415085247 accession number:		0000895345-11-000132 conformed submission type:	sc 13d public document count:		3 filed as of date:		20110415 date as of change:		20110415 group members:		monarch transaction corp. subject company:	 	company data:	 		company conformed name:			inspire pharmaceuticals inc 		central index key:			0001040416 		standard industrial classification:	pharmaceutical preparations [2834] 		irs number:				043209022 		state of incorporation:			de 		fiscal year end:			1231 	filing values: 		form type:		sc 13d 		sec act:		1934 act 		sec file number:	005-60379 		film number:		11761088 	business address:	 		street 1:		4222 emperor blvd ste 200 		city:			durham 		state:			nc 		zip:			27703-8466 		business phone:		9199419777 	mail address:	 		street 1:		4222 emperor blvd 		street 2:		ste 200 		city:			durham 		state:			nc 		zip:			27703-8466 filed by:		 	company data:	 		company conformed name:			merck & co. inc. 		central index key:			0000310158 		standard industrial classification:	pharmaceutical preparations [2834] 		irs number:				221918501 		state of incorporation:			nj 		fiscal year end:			1231 	filing values: 		form type:		sc 13d 	business address:	 		street 1:		one merck drive 		street 2:		p.o. box 100 		city:			whitehouse station 		state:			nj 		zip:			08889-0100 		business phone:		908-423-4840 	mail address:	 		street 1:		one merck drive 		street 2:		p.o. box 100 		city:			whitehouse station 		state:			nj 		zip:			08889-0100 	former company:	 		former conformed name:	schering plough corp 		date of name change:	19920703 sc 13d 1 ds13-inspire_merck.htm ds13-inspire_merck.htm &#160; &#160; &#160; &#160; united states securities and exchange commission washington, d.c. 20549 &#160; &#160; schedule 13d &#160; under the securities exchange act of 1934 &#160; inspire pharmaceuticals, inc. (name of issuer) &#160; common stock, par value $0.001 per share (title of class of securities) 457733103 (cusip number) &#160; &#160; celia colbert senior vice president, secretary, and assistant general counsel merck &amp; co., inc. one merck drive whitehouse station, nj 08889-0100 (908) 423-1000 copies to: david n. shine fried, frank, harris, shriver &amp; jacobson llp one new york plaza new york, ny 10004-1980 (212)&#160;&#160;859-8000 (name, address and telephone number of person authorized to receive notices and communications) &#160; april 5, 2011 (date of event which requires filing of this statement) &#160; if the filing person has previously filed a statement on schedule 13g to report the acquisition that is the subject of this schedule 13d, and is filing this schedule because of &#167;&#167; 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box:&#160; o &#160; note : schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. see &#167;240.13d-7 for other parties to whom copies are to be sent. &#160; *the remainder of this cover page shall be filled out for a reporting person&#8217;s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. &#160; the information required on the remainder of this cover page shall not be deemed to be &#8220;filed&#8221; for the purpose of section 18 of the securities exchange act of 1934 (&#8220;act&#8221;) or otherwise subject to the liabilities of that section of the act but shall be subject to all other provisions of the act (however, see the notes). &#160; &#160; &#160; &#160; &#160; schedule 13d &#160; cusip no.&#160;&#160;457733103 &#160; page 2 of 8 &#160; &#160; 1 name of reporting person i.r.s. identification no. of above person (entities only) &#160; merck &amp; co., inc. 22-1918501 2 check the appropriate box if a member of a group (a)&#160; o (b)&#160; x &#160; 3 sec use only &#160; 4 source of funds wc &#160; 5 check if disclosure of legal proceedings is required pursuant to items 2(d) or 2(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; o 6 citizenship or place of organization new jersey &#160; number of 7 sole voting power 0 &#160; shares beneficially 8 shared voting power 22,907,488 &#160; owned by each 9 sole dispositive power 0 &#160; reporting person with 10 shared dispositive power 22,907,488 &#160; 11 aggregate amount beneficially owned by each reporting person 22,907,488 &#160; 12 check if the aggregate amount in row (11) excludes certain shares &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; o &#160; 13 percent of class represented by amount in row (11) 27.5% &#160; 14 type of reporting person co &#160; &#160; &#160; &#160; &#160; &#160; &#160; cusip no.&#160;&#160;457733103 &#160; page 3 of 8 &#160; 1 name of reporting person i.r.s. identification no. of above person (entities only) &#160; monarch transaction corp. 45-1540007 2 check the appropriate box if a member of a group (a)&#160; o (b)&#160; x &#160; 3 sec use only &#160; 4 source of funds wc &#160; 5 check if disclosure of legal proceedings is required pursuant to items 2(d) or 2(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; o 6 citizenship or place of organization delaware &#160; number of 7 sole voting power 0 &#160; shares beneficially 8 shared voting power 22,907,488 &#160; owned by each 9 sole dispositive power 0 &#160; reporting person with 10 shared dispositive power 22,907,488 &#160; 11 aggregate amount beneficially owned by each reporting person 22,907,488 &#160; 12 check if the aggregate amount in row (11) excludes certain shares &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; o &#160; 13 percent of class represented by amount in row (11) 27.5% &#160; 14 type of reporting person co &#160; &#160; &#160; &#160; &#160; page 4 of 8 &#160; &#160; item 1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;security and issuer &#160; this schedule 13d relates to the common stock, par value $0.001 per share (the &#8220;common stock&#8221;), of inspire pharmaceuticals, inc., a delaware corporation (&#8220;inspire&#8221;), and the associated preferred stock purchase rights (the &#8220;rights&#8221;, and together with the common stock, each, a &#8220;share&#8221;, and collectively, the &#8220;shares&#8221;).&#160;&#160;the principal executive offices of inspire are located at 8081 arco corporate drive, suite 400, raleigh, north carolina. &#160; item 2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;identity and background &#160; (a)-(c), (f):&#160;&#160;this schedule 13d is being filed jointly on behalf of merck &amp; co., inc., a company formed under the laws of new jersey (&#8220;merck&#8221;), and monarch transaction corp., a delaware corporation and a wholly-owned subsidiary of merck (&#8220;purchaser&#8221;), pursuant to a joint filing agreement attached hereto as exhibit 7.01.&#160;&#160;merck is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. &#160; purchaser is a wholly-owned subsidiary of merck, formed for the sole purpose of engaging in the transactions contemplated by the merger agreement (as defined below). &#160; the address of merck&#8217;s and purchaser&#8217;s principal executive offices is one merck drive, whitehouse station, nj 08889-0100.&#160;&#160;the name, business address, citizenship and present principal occupation of each executive officer and director of merck and purchaser are set forth in annex i and annex ii to this schedule 13d, respectively, which are incorporated herein by reference. &#160; (d)-(e):&#160;&#160;during the five years prior to the date hereof, neither merck or purchaser nor, to the best knowledge of merck and purchaser, any person listed on annex i or annex ii to this schedule 13d, respectively, have been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which it was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. &#160; item 3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;source and amount of funds or other consideration &#160; merck, purchaser and inspire have entered into a definitive agreement and plan of merger, dated as of april 5, 2011 (as amended from time to time, the &#8220;merger agreement&#8221;).&#160;&#160;subject to the terms and conditions thereof, merck will cause purchaser to commence a tender offer (as it may be amended from time to time, the &#8220;offer&#8221;) to purchase all the issued and outstanding shares at a price per share of $5.00 net to the seller in cash, without interest (such amount, or any higher amount per share paid pursuant to the offer in accordance with the merger agreement, the &#8220;offer price&#8221;).&#160;&#160;as soon as practicable after the consummation of the offer and satisfaction or waiver of certain conditions set forth in the merger agreement, purchaser will merge with and into inspire (the &#8220;merger&#8221;) and inspire will become a wholly-owned subsidiary of the merck (the &#8220;surviving corporation&#8221;). &#160; as an inducement for merck and purchaser to enter into the merger agreement with inspire, and in consideration thereof, warburg pincus private equity ix, l.p., a limited partnership organized under the laws of delaware (&#8220;warburg&#8221;) entered into a tender and support agreement, dated as of april 5, 2011, with merck and purchaser (the &#8220;tender and support agreement&#8221;). for descriptions of the merger agreement and tender and support agreement, see item 4 below, which descriptions are incorporated herein by reference in response to this item 3.&#160;&#160;such descriptions do not purport to be complete and are qualified in their entirety by reference to the merger agreement, a copy of which is attached hereto as exhibit 7.02, and the tender and support agreement, a copy of which is attached hereto as exhibit 7.03, and which are incorporated herein by reference.&#160;&#160;this schedule 13d does not purport to amend, qualify, or in any way modify the merger agreement and the tender and support agreement. item 4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;purpose of transaction &#160; the information set forth and/or incorporated by reference in items 2 and 3 is hereby incorporated by reference into this item 4.&#160;&#160;as stated above, the tender and support agreement was entered into as an inducement for, and in consideration of, merck and purchaser entering into the merger agreement. &#160; merger agreement &#160; upon the purchase of shares pursuant to the&#160;offer, the merger agreement provides that purchaser will be entitled to designate the number of directors, rounded up to the next whole number, to the inspire board of directors (the &#8220;inspire board&#8221;) that is in the same proportion as the shares beneficially owned by merck, purchaser or any other subsidiary of merck to the total number of shares then outstanding. purchaser currently intends, promptly after consummation of the&#160;offer, to exercise this right and to designate new directors of inspire from among (and possibly including all of) the following potential designees: richard n. kender, steven koehler, mark e. mcdonough, james mcintyre, sean t. mooney and george shiebler. each potential designee is a director, officer or employee of merck. merck and purchaser would expect that such representation on the inspire board would permit merck and purchaser to exert substantial influence over inspire&#8217;s conduct of its business and operations. purchaser currently intends, as soon as practicable after consummation of the&#160;offer, to consummate the merger pursuant to the merger agreement.&#160;&#160;purchaser&#8217;s directors immediately prior to the effective time of the merger (the &#8220;effective time&#8221;) will be the initial directors of the surviving corporation. the merger agreement provides that prior to the effective time, inspire will cooperate with merck and use its commercially reasonable efforts to take all actions and do all things reasonably necessary, proper or advisable under applicable laws and nasdaq rules to enable the de-listing of the common stock of the surviving corporation from nasdaq and the deregistration of the common stock under the act as promptly as practicable after the effective time. at the effective time and as a result of the merger, (i) each share of purchaser capital stock will be converted into and become one validly issued, fully paid and nonassessable share of common stock, par value $0.01 per share, of the surviving corporation and (ii) each share issued and outstanding immediately prior to the effective time (other than shares held in treasury of inspire and each share owned by merck, purchaser or inspire, which will be cancelled, and any holder of shares who properly demands appraisal of such shares) will be canceled and extinguished and automatically converted into the right to receive an amount of cash equal to the offer price (the &#8220;merger consideration&#8221;).&#160;&#160;the merger agreement provides that inspire will take all reasonble&#160; steps necessary to provide that&#160;all options,&#160;whether vested or unvested, to purchase shares of&#160;common stock will become fully vested immediately prior to the acceptance for payment (the &#8220;acceptance time&#8221;) of all the shares validly tendered and not properly withdrawn during the initial offering period (including extensions) and will be canceled as of the acceptance time in exchange for the right to receive, without interest, a lump sum cash amount (less any applicable withholding taxes) equal to the excess, if any, of the offer price over the per share exercise price of such option multiplied by the number of shares of inspire common stock issuable upon exercise of such option. the merger agreement further provides that inspire will take all reasonable steps necessary to provide that&#160;each outstanding award of restricted stock&#160;&#160;units, whether vested or unvested, will become fully vested and all restrictions and conditions applicable thereto will lapse immediately prior to the acceptance time and be canceled as of the acceptance time and converted into the right to receive, without interest, a cash payment equal to the offer price (less any applicable withholding taxes). at the effective time, the certificate of incorporation of the surviving corporation will be amended in its entirety as set forth in exhibit c to the merger agreement, until thereafter amended as provided under the general corporation law of the state of delaware. tender and support agreement as an inducement to merck and purchaser entering into the merger agreement, and in consideration thereof, warburg, merck and purchaser entered into the tender and support agreement, whereby warburg agreed, among other things, to tender its shares in the&#160;offer for the offer price and support any and all corporate action necessary to consummate the merger, including granting merck a limited irrevocable proxy to vote the covered shares (as defined below) in furtherance of the foregoing.&#160;&#160;merck and purchaser did not pay any additional consideration to warburg in connection with the execution and delivery of the tender and support agreement. among other things, the tender and support agreement provides that (i) warburg, as of the date of the tender and support agreement, is the beneficial owner of 22,907,488 shares, or approximately twenty seven and one half percent (27.5%) of the outstanding shares (&#8220;covered shares&#8221;), (ii) warburg will vote all of the covered shares in favor of the approval of the merger and the approval and adoption of the merger agreement and against any alternative proposal, (iii) warburg will not sell, transfer, gift or otherwise dispose of any of the covered shares (other than to an affiliate, subsidiary, partner or member of warburg) or grant any proxies or powers of attorney with respect to any of the covered shares in contravention of the obligations under the tender and support agreement, and (iv) warburg will not subject any covered shares to any pledges, liens or other encumbrances or arrangements.&#160;&#160;warburg has also agreed not to take any action, in its capacity as a stockholder of inspire, that inspire is prohibited from taking pursuant to section 6.8 of the merger agreement. additionally, warburg granted merck an irrevocable option (the &#8220;option&#8221;) to purchase covered shares at the offer price if (i) purchaser acquires shares pursuant to the offer and (ii) warburg fails to tender into the offer all of the covered shares or withdraws the tender of any covered shares in breach of the tender and support agreement.&#160;&#160;&#160;merck may exercise the option at any time within the sixty (60) days following the date when the option first becomes exercisable. the tender and support agreement will terminate upon the earlier of (i) the effective time, (ii)&#160;the date of any modification, waiver, change or amendment of the offer or the merger agreement that results in&#160;(a) a decrease in the offer price or merger consideration or (b) a change in the form of consideration to be paid in the offer or in the form of merger consideration, and (iii) the termination of the merger agreement in accordance with its terms. except as set forth in this item 4, neither merck and purchaser nor, to merck and purchaser&#8217;s knowledge, any of the individuals referred to in annex i and annex ii, to this schedule 13d, respectively, has any plans or proposals which relate to or would result in any of the actions specified in clauses (a)-(j) of item 4 of schedule 13d. &#160; &#160; &#160; &#160; &#160; &#160; page&#160;5 of 8 &#160; the foregoing summaries of certain provisions of the merger agreement and the tender and support agreement do not purport to be complete and are qualified in their entirety by reference to the merger agreement, a copy of which is attached hereto as exhibit 7.02, and the tender and support agreement, a copy of which is attached hereto as exhibit 7.03, and which are incorporated herein by reference in their entirety.&#160;&#160;this schedule 13d does not purport to amend, qualify, or in any way modify the merger agreement and the tender and support agreement. item 5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;interest in securities of the issuer &#160; (a)-(b)&#160;&#160;&#160;pursuant to the tender and support agreement, merck and purchaser may be deemed to have (i) beneficial ownership of shares, (ii) shared power to vote or direct the vote of 22,907,488 shares, or approximately twenty seven and one half percent (27.5%) of the shares deemed to be outstanding pursuant to rule 13d-3 of the act, subject to the terms and conditions of the tender and support agreement, and (iii) shared power to dispose or direct the disposition of&#160;&#160;22,907,488 shares, or approximately twenty seven and one half percent (27.5%) of the shares deemed to be outstanding pursuant to rule 13d-3 of the act, subject to the terms and conditions of the tender and support agreement.&#160;&#160;such percentage is based on the 83,292,192 shares of common stock outstanding as of april 1, 2011, as represented by inspire in the merger agreement.&#160;&#160;neither the filing of this schedule 13d nor any of its contents shall be deemed to constitute an admission by merck and purchaser that they are the beneficial owner of any of the shares referred to herein for purposes of section 13(d) of the act, or for any other purpose, and such beneficial ownership is expressly disclaimed. &#160; apart from the terms and conditions set forth in the tender and support agreement, merck and purchaser are not entitled to any rights of a stockholder of inspire.&#160;&#160;merck does not, other than as specified in the tender and support agreement, have (i) sole or shared power to vote or direct the vote or (ii) sole or shared power to dispose or direct the disposition of, shares. &#160; (c)&#160;&#160;except as set forth or incorporated herein, neither merck and purchaser nor, to merck and purchaser&#8217;s knowledge, any of the individuals referred to in annex i and annex ii to this schedule 13d, respectively, have effected any transaction in the shares during the past 60 days. &#160; (d)&#160;&#160;not applicable. &#160; (e)&#160;&#160;not applicable. &#160; item 6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; contracts, arrangements, understandings or relationships with respect to securities of the issuer &#160; other than the merger agreement and the tender and support agreement, to the knowledge of merck and purchaser, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in annex i and annex ii to this schedule 13d, respectively, or between such persons and any other person with respect to the securities of inspire, including, but not limited to, transfer or voting of any securities, finder&#8217;s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies. &#160; item 7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;material to be filed as exhibits &#160; 7.01 joint filing agreement, dated as of april 15, 2011, by and among merck and purchaser. &#160; 7.02 agreement and plan of merger, dated as of april 5, 2011, by and among merck, purchaser and inspire (incorporated herein by reference to exhibit 2.1 to inspire&#8217;s current report on form 8-k, file no. 001-31577, filed with the u.s. securities and exchange commission on april 8, 2010). &#160; 7.03 tender and support agreement, dated as of april 5, 2011, by and among merck, purchaser and warburg. &#160; &#160; &#160; &#160; &#160; page&#160;6 of 8 &#160; signature &#160; after reasonable inquiry and to the best of my knowledge and belief of each of the undersigned, the undersigned certify that the information set forth in this statement is true, complete and correct. &#160; date:&#160;&#160;april 15, 2011 merck &amp; co., inc. &#160; by:&#160;&#160;&#160;&#160;&#160; /s/ katie fedosz &#160; name: katie fedosz title:&#160;&#160;&#160;senior assistant secretary &#160; &#160; &#160; &#160; date:&#160;&#160;april 15, 2011 monarch transaction corp. &#160; by:&#160;&#160;&#160;&#160;&#160; /s/ katie fedosz &#160; name: katie fedosz title:&#160;&#160;&#160;assistant secretary &#160; &#160; &#160; &#160; &#160; &#160; page&#160;7 of 8 &#160; annex i executive officers and directors of merck &amp; co., inc. the name, present principal occupation or employment, and the name, principal business and address of any corporation or other organization in which such employment is conducted, of each of the executive officers and directors of merck &amp; co., inc. is set forth below. &#160; &#160; &#160; name (citizenship) business address principal occupation kenneth c. frazier (united states of america) one merck drive, whitehouse station, n. j. 08889 president and chief executive officer / director, merck &amp; co., inc. adele d. ambrose (united states of america) one merck drive, whitehouse station, n. j. 08889 senior vice president and chief communications officer, merck &amp; co., inc. richard s. bowles iii (united states of america) one merck drive, whitehouse station, n. j. 08889 executive vice president and chief compliance officer, merck &amp; co., inc. john canan&#160;&#160;(canada) one merck drive, whitehouse station, n. j. 08889 senior vice president finance-global controller, merck &amp; co., inc. willie a. deese&#160;&#160;(united states of america) one merck drive, whitehouse station, n. j. 08889 executive vice president and president, merck manufacturing division (&#8220;mmd&#8221;), merck &amp; co., inc. mirian m. graddick-weir (united states of america) one merck drive, whitehouse station, n. j. 08889 executive vice president, human resources, merck &amp; co., inc. bridgette p. heller (united states of america) one merck drive, whitehouse station, n. j. 08889 executive vice president and president, merck consumer care, merck &amp; co., inc. peter n. kellogg (united states of america) one merck drive, whitehouse station, n. j. 08889 executive vice president and chief financial officer, merck &amp; co., inc. peter s. kim (united states of america) one merck drive, whitehouse station, n. j. 08889 executive vice president and president, merck research laboratories, merck &amp; co., inc. raul e. kohan (united states of america) one merck drive, whitehouse station, n. j. 08889 executive vice president and president, animal health, merck &amp; co., inc. bruce n. kuhlik (united states of america) one merck drive, whitehouse station, n. j. 08889 executive vice president and general counsel, merck &amp; co., inc. michael rosenblatt, m.d. (united states of america) one merck drive, whitehouse station, n. j. 08889 executive vice president and chief medical officer, merck &amp; co., inc. j. chris scalet (united states of america) one merck drive, whitehouse station, n. j. 08889 executive vice president, global services, and chief information officer, merck &amp; co., inc. adam h. schechter (united states of america) one merck drive, whitehouse station, n. j. 08889 executive vice president and president, global human health, merck &amp; co., inc. mervyn turner (united states of america) one merck drive, whitehouse station, n. j. 08889 chief strategy officer and senior vice president, merck research laboratories, merck &amp; co., inc. richard t. clark (united states of america) one merck drive, whitehouse station, n. j. 08889 chairman of the board of directors, merck &amp; co., inc. leslie a. brun (united states of america) 435 devon park drive, 700 building, wayne, pa&#160;&#160;19087 chairman and chief executive officer, sarr group, llc thomas r. cech (united states of america) university of colorado, university chemistry building 215, boulder, co&#160;&#160;80309-0215 investigator, howard hughes medical institute and faculty, university of colorado. thomas h. glocer (united states of america) 3 times square, 30 th floor, new york, ny&#160;&#160;10036 chief executive officer, thomson reuters corporation steven f. goldstone (united states of america) 445 main street, ridgefield, ct&#160;&#160;06877 managing partner, silver spring group william b. harrison, jr. (united states of america) 277 park avenue, 35 th floor, new york, ny&#160;&#160;10172-0003 retired chairman of the board, jpmorgan chase &amp; co. harry r. jacobson (united states of america) 3401 west end avenue, nashville, tn&#160;&#160;37203 vice chancellor, health affairs, emeritus, vanderbilt university william n. kelley (united states of america) 421 curie blvd., philadelphia, pa&#160;&#160;19104-6160 professor of medicine, biochemistry and biophysics, university of pennsylvania school of medicine c. robert kidder (united states of america) 191 west nationwide boulevard, suite 600, columbus, oh&#160;&#160;43215 chairman and chief executive officer, 3stone advisors llc rochelle b. lazarus (united states of america) 636 11 th avenue, new york, ny&#160;&#160;10036-2010 chairman, ogilvy &amp; mather worldwide carlos e. represas (mexico and spain) av. ejercito nacional no. 453, colonia granada, 11520 mexico, d.f., mexico retired chairman, grupo nestle mexico patricia f. russo (united states of america) 600 mountain avenue, murray hill, nj&#160;&#160;07974 retired chief executive officer and director, alcatel-lucent thomas e. shenk (united states of america) washington road, princeton, nj&#160;&#160;08544-1014 elkins professor, department of molecular biology, princeton university anne m. tatlock (united states of america) c/o merck &amp; co., inc., one merck drive, whitehouse station, nj&#160;&#160;08889 retired chairman of the board, fiduciary trust company international craig b. thompson (united states of america) memorial sloan-kettering cancer center, 1275 york avenue, new york, ny&#160;&#160;10065 president and chief executive officer of memorial sloan-kettering cancer center and professor of medicine at the university of pennsylvania school of medicine wendell p. weeks (united states of america) 1 riverfront plaza, corning, ny&#160;&#160;14831-0001 president, chairman and chief executive officer, corning incorporated peter c. wendell (united states of america) 2884 sand hill road, suite 100, menlo park, ca&#160;&#160;94025-7072 managing director, sierra ventures &#160; &#160; &#160; &#160; &#160; page&#160;8 of 8 &#160; &#160; annex ii executive officers and directors of monarch transaction corp. the name, present principal occupation or employment, and the name, principal business and address of any corporation or other organization in which such employment is conducted, of each of the executive officers and directors of monarch transaction corp. is set forth below. name (citizenship) business address principal occupation richard n. kender (united states of america) one merck drive, whitehouse station, n. j. 08889-0100 senior vice president, business development &amp; corporate licensing, merck &amp; co., inc. mark e. mcdonough (united states of america) one merck drive, whitehouse station, n. j. 08889-0100 vice president and treasurer, merck &amp; co., inc. sean t. mooney (united states of america) one merck drive, whitehouse station, n. j. 08889-0100 assistant treasurer, merck &amp; co., inc. jon filderman (united states of america) one merck drive, whitehouse station, n. j. 08889-0100 managing counsel - corporate legal group, merck &amp; co., inc. katie e. fedosz (united states of america and poland) one merck drive, whitehouse station, n. j. 08889-0100 senior assistant secretary, merck &amp; co., inc. &#160; &#160; &#160; ex-7.01 2 ds13dex7_01.htm ds13dex7_01.htm &#160; &#160; &#160; exhibit 7.01 joint filing agreement in accordance with rule 13d-1(k) under the securities exchange act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on schedule 13d (including amendments thereto) with respect to the capital stock of inspire pharmaceuticals, inc. date:&#160;&#160;april 15, 2011 merck &amp; co., inc. &#160; by:&#160;&#160;&#160;&#160;&#160; /s/ katie fedosz &#160; name: katie fedosz title:&#160;&#160;&#160;senior assistant secretary &#160; date:&#160;&#160;april 15, 2011 monarch transaction corp. &#160; by:&#160;&#160;&#160;&#160;&#160; /s/ katie fedosz &#160; name: katie fedosz title:&#160;&#160;&#160;assistant secretary &#160; ex-7.03 3 ds13dex7_03.htm ds13dex7_03.htm &#160; &#160; &#160; &#160; exhibit 7.03 tender and support agreement &#160; this tender and support agreement (this &#8220; agreement &#8221;) dated as of april 5, 2011, is entered into by and among merck &amp; co. inc., a company formed under the laws of new jersey (&#8220; parent &#8221;), monarch transaction corp., a delaware corporation and wholly-owned subsidiary of parent (&#8220; purchaser &#8221;) and warburg pincus private equity ix, l.p., a limited partnership organized under the laws of delaware (&#8220; stockholder &#8221;). &#160; witnesseth: &#160; whereas, parent, purchaser and inspire pharmaceuticals, inc., a delaware corporation (the &#8220; company &#8221;), have entered into an agreement and plan of merger, dated as of the date hereof (as may be amended, modified or supplemented from time to time, the &#8220; merger agreement &#8221;) pursuant to which parent has agreed to cause purchaser to make a cash tender offer to purchase all the issued and outstanding shares of common stock, par value $0.001 per share (the &#8220; company common stock &#8221;) of the company and the associated preferred stock purchase rights (the &#8220; rights &#8221;, and together with the company common stock, each, a &#8220; share &#8221;, and collectively, the &#8220; shares &#8221;) at a price per share of $5.00 net to the seller in cash, without interest (such amount, or any higher amount per share paid pursuant to the offer in accordance with the merger agreement, the &#8220; offer price &#8221;), and thereafter merge with and into the company (the &#8220; merger &#8221;) with the result that the company becomes a wholly-owned subsidiary of the parent; &#160; whereas, stockholder is, as of the date hererof, the beneficial owner (as defined in rule 13d-3 under the securities exchange act of 1934, as amended (the &#8220; exchange act &#8221;)) of such number of shares set forth opposite the name of stockholder on schedule i attached hereto (such shares, together with any shares or other securities of the company (including all additional shares of capital stock of the company and all additional options, warrants and other rights to acquire shares of capital stock of the company) of which stockholder obtains beneficial ownership after the date hereof, being collectively referred to herein as the &#8220; covered shares &#8221; of stockholder); &#160; whereas, parent and purchaser desire to enter into this agreement in connection with their efforts to consummate the acquisition of the company; &#160; whereas , stockholder has agreed to convey to parent and purchaser pursuant to and subject to the terms of this agreement beneficial ownership of all of the covered shares; and &#160; whereas, capitalized terms used in this agreement and not defined have the meaning given to such terms in the merger agreement. &#160; now, therefore, in contemplation of the foregoing and in consideration of the mutual agreements, covenants, representations and warranties contained herein and intending to be legally bound hereby, the parties hereto agree as follows: &#160; 1. &#160;&#160;&#160; certain covenants . &#160; 1.1 &#160;&#160;&#160; lock-up .&#160;&#160;subject to section 1.5, except as contemplated by the merger agreement, stockholder hereby covenants and agrees that between the date hereof and the termination date (as defined below), stockholder shall not (a) directly or indirectly, sell, transfer, assign, pledge, hypothecate, tender, gift, place in trust or otherwise dispose of or limit its right, title or interest or right to vote in any manner any of the covered shares, or agree to do any of the foregoing, (b) grant any proxies or powers of attorney with respect to any of the covered shares, deposit any of the covered shares into a voting trust or enter into a voting agreement or other similar commitment or arrangement with respect to any of the covered shares in contravention of the obligations of stockholder under this agreement or (c) permit any covered shares to be, or become subject to any liens (as defined below). notwithstanding the foregoing, in connection with any transfer not involving or relating to any takeover proposal, stockholder may transfer any or all of the covered shares to any affiliate, subsidiary, partner or member of stockholder; provided , however , that in any such case, prior to and as a condition to the effectiveness of such transfer, (a) each person to which any of such covered shares or any interest in any of such covered shares is or may be transferred shall have executed and delivered to parent and purchaser a counterpart to this agreement pursuant to which such person shall be bound by all of the terms and provisions of this agreement, and (b) this agreement shall be the legal, valid and binding agreement of such person, enforceable against such person in accordance with its terms. &#160; 1.2 &#160;&#160;&#160; no solicitations .&#160;&#160;between the date hereof and the termination date, stockholder agrees neither stockholder nor stockholder&#8217;s officers or directors shall, and stockholder shall not, and shall not authorize or permit, any agent, representative, employee, affiliate, advisor, attorney, accountant, investment banker, consultant or associate of stockholder or those of its subsidiaries (collectively, &#8220; representatives &#8221;) to, directly or indirectly, take any action that the company is prohibited from taking pursuant to section 6.8 of the merger agreement. &#160; 1.3 &#160;&#160;&#160; certain events .&#160;&#160;this agreement and the obligations hereunder will attach to the covered shares and will be binding upon any person to which legal or beneficial ownership of any or all of the covered shares passes, whether by operation of law or otherwise, including without limitation, stockholder&#8217;s successors or assigns. this agreement and the obligations hereunder will also attach to any additional shares of common stock issued to or acquired by stockholder, but such additional shares shall not be optioned shares (as defined below) for purposes of this agreement. &#160; 1.4 &#160;&#160;&#160; grant of proxy; voting agreement . &#160; (a) &#160; stockholder has revoked or terminated any and all proxies, voting agreements or similar arrangements previously given or entered into with respect to the covered shares and hereby grants parent until the termination date a limited irrevocable proxy to vote the covered shares as to which such stockholder has voting power for such stockholder and in such stockholder&#8217;s name, place and stead, at any annual or special meeting of the stockholders of the company, as applicable, or at any adjournment thereof, whether before or after the acceptance time, solely (i) for the adoption of the merger agreement and the approval of the merger, including each other action, agreement and transaction in furtherance of the offer, the merger agreement, merger and this agreement, to the extent contemplated thereby and hereby, (ii) against approval of any proposal made in opposition to, or in competition with, consummation of the offer or the merger and the transactions contemplated by the merger agreement, (iii) except as otherwise agreed to in writing in advance by purchaser, against any other action, proposal, transaction or agreement that would compete with or interfere with, delay, discourage, adversely affect or inhibit the timely consummation of the offer or the merger and (iv) as directed by parent or purchaser with respect to any takeover proposal.&#160;&#160;the proxy granted by stockholder pursuant to this section 1.4 is coupled with an interest and is irrevocable and is granted in consideration of purchaser entering into this agreement and incurring certain related fees and expenses.&#160;&#160;notwithstanding the foregoing, the proxy granted by this section 1.4 shall be revoked upon the termination date.&#160;&#160;such irrevocable proxy is executed and intended to be irrevocable in accordance with section 212 of the dgcl. except as expressly set forth herein, parent acknowledges (i) that the proxy granted hereby shall not be effective for any other purpose, and (ii) such proxy shall not limit the rights of the stockholder to vote or exercise its rights to consent in favor of or against, or abstain with respect to, any matter presented to the company&#8217;s stockholders that is not subject to the limited irrevocable proxy granted to parent in respect of the covered shares pursuant to the first sentence of this section 1.4(a).&#160;&#160;the proxy granted hereunder shall be automatically revoked upon termination of this agreement in accordance with its terms. the parties acknowledge and agree that neither parent, nor parent&#8217;s successors, assigns, subsidiaries, divisions, employees, officers, directors, stockholders, agents and affiliates shall owe any duty to, whether in law or otherwise, or incur any liability of any kind whatsoever, including without limitation, with respect to any and all claims, losses, demands, causes of action, costs, expenses (including reasonable attorney&#8217;s fees) and compensation of any kind or nature whatsoever to stockholder in connection with or as a result of any voting by parent of the covered shares subject to the irrevocable proxy hereby granted to parent at any annual or special meeting of the stockholders of the company for the purpose set forth herein. &#160; (b) &#160; this irrevocable proxy shall not be terminated by any act of stockholder or by operation of law (including, without limiting the foregoing, by the dissolution or liquidation of any corporation or partnership). if between the execution hereof and the termination date, if any corporation or partnership holding the covered shares should be dissolved or liquidated, or if any other such similar event or events shall occur before the termination date, certificates representing the covered shares shall be delivered by or on behalf of stockholder in accordance with the terms and conditions of the merger agreement and this agreement, and actions taken by parent hereunder shall be as valid as if such dissolution, liquidation or other similar event or events had not occurred, regardless of whether or not parent has received notice of such dissolution, liquidation or other event. &#160; 1.5 &#160;&#160;&#160; tender of shares .&#160;&#160;stockholder agrees, in exchange for the offer price, to tender the covered shares to purchaser in the offer not later than five (5) business days following the commencement of the offer (such covered shares being referred to herein as the &#8220; tender shares &#8221;); provided , however , that stockholder may withdraw any tender shares so tendered above at any time following the termination date; provided , further , that stockholder shall not have any obligation under this section 1.5 to tender the tender shares into the offer if that tender could cause stockholder to incur liability under section 16(b) of the exchange act. &#160; 1.6 &#160;&#160;&#160; option . &#160; (a) &#160; on the terms and subject to the conditions set forth herein, stockholder hereby grants to parent an irrevocable option (the &#8220; option &#8221;) to purchase all of the right, title and interest of the stockholder in and to all of the covered shares (the &#8220; optioned shares &#8221;) with a price per share equal to the offer price.&#160;&#160;parent may exercise the option only if (i) purchaser has acquired shares of common stock pursuant to the offer and (ii) stockholder has failed to tender into the offer all of the covered shares or shall have withdrawn the tender of any covered shares in breach of this agreement.&#160;&#160;parent may exercise the option at any time within the sixty (60) days following the date when such option first becomes exercisable. &#160; (b) &#160; in the event that parent is entitled to and wishes to exercise the option, parent shall send a written notice to stockholder specifying the place and the date for the closing of such purchase, which date shall be not more than sixty (60) days after the date of such notice; provided , that in the event that prior notification to, or approval of, any governmental authority is required in connection with the exercise of the option or there shall be in effect any preliminary or final injunction or other order issued by any governmental authority prohibiting the exercise of the option, the period of time during which the date of the closing may be fixed shall be extended until the tenth (10th) day following the last date on which all required approvals shall have been obtained, all required waiting periods shall have expired or been terminated and any such prohibition shall have been vacated, terminated or waived. &#160; (c) &#160; at the closing of the purchase of the optioned shares pursuant to exercise of the option, simultaneously with the payment by parent of the purchase price for stockholder&#8217;s optioned shares, stockholder shall deliver, or cause to be delivered, to purchaser certificates representing the optioned shares duly endorsed to parent or accompanied by stock powers or other transfer documents duly executed by the company in blank, together with any necessary stock transfer stamps properly affixed, free and clear of all liens. &#160; (d) &#160; the parent, purchaser or the company, as applicable, shall be entitled to deduct and withhold from the consideration otherwise payable pursuant to this section 1.6 to stockholder such amounts as are required to be withheld under the code or the treasury regulations or any other tax law. &#160; 1.7 &#160;&#160;&#160; waiver of appraisal and dissenters&#8217; rights and actions .&#160;&#160;stockholder hereby (a) waives and agrees not to exercise any rights of appraisal or rights to dissent from the merger that stockholder may have and (b) agrees not to commence or participate in, and agrees to take all actions necessary to opt out of any class in any class action with respect to, any claim, derivative or otherwise, against parent, purchaser, the company or any of their respective successors challenging the validity of, or seeking to enjoin the operation of, any provision of this agreement or the merger agreement or the consummation of the offer or the merger. &#160; 1.8 &#160;&#160;&#160; public announcement .&#160;&#160;stockholder shall consult with parent before issuing any press releases or otherwise making any public statements with respect to the transactions contemplated herein and shall not issue any such press release or make any such public statement without the approval of parent (which approval shall not be unreasonably withheld, conditioned or delayed), except as may be required by law, including any filings with the sec pursuant to the exchange act.&#160;&#160;this section 1.8 shall terminate and be of no further force or effect upon the earlier of (a) the termination date and (b) consummation of the merger. &#160; 1.9 &#160;&#160;&#160; disclosure .&#160;&#160;stockholder hereby authorizes parent and purchaser to publish and disclose in any announcement or disclosure required by the sec, the nasdaq stock market or any other national securities exchange and in the offer documents and, if necessary, the proxy statement (including all documents and schedules filed with the sec in connection with either of the foregoing), stockholder&#8217;s identity and ownership of the covered shares and the nature of stockholder&#8217;s commitments, arrangements and understandings under this agreement. parent and purchaser hereby authorize stockholder to make such disclosure or filings as may be required by the sec or the nasdaq stock market or any other national securities exchange. &#160; 2. &#160;&#160;&#160; representations and warranties of stockholder .&#160;&#160;stockholder hereby represents and warrants to parent and purchaser, as of the date hereof and at all times until the termination date, that: &#160; 2.1 &#160;&#160;&#160; ownership .&#160;&#160;as of the date hereof, stockholder is the record holder or beneficially holds all of the covered shares set forth on schedule i , in each case, except as set forth on schedule i , free and clear of all liabilities, claims, liens, options, proxies, charges, participations and encumbrances of any kind or character whatsoever, other than those arising under the securities laws or under the company&#8217;s governance documents (collectively, &#8220; liens &#8221;). at the time purchaser purchases tender shares from stockholder pursuant to the offer, stockholder will transfer and convey to purchaser good and marketable title to such tender shares, free and clear of all liens created by or arising through stockholder. &#160; 2.2 &#160;&#160;&#160; authorization .&#160;&#160;stockholder has the legal capacity, power and authority to execute, deliver and perform all of stockholder&#8217;s obligations under this agreement and to consummate the transactions contemplated hereby and has the power to vote and the power to dispose of the covered shares with no restrictions on its voting rights or rights of disposition pertaining thereto, except as set forth in this agreement or that may exist pursuant to the securities laws.&#160;&#160;stockholder has duly and validly executed and delivered this agreement and this agreement is a legal, valid and binding agreement of stockholder, enforceable against stockholder in accordance with its terms, except to the extent enforceability may be limited by the effect of applicable bankruptcy, reorganization, insolvency, moratorium or other laws affecting the enforcement of creditors&#8217; rights generally and the effect of general principles of equity, regardless of whether such enforceability is considered in a proceeding at law or in equity. &#160; 2.3 &#160;&#160;&#160; no violation .&#160;&#160;neither the execution, delivery and performance of this agreement nor the consummation of the transactions contemplated hereby will (a) require stockholder to notify, file or register with, or obtain any permit, authorization, consent or approval of, any governmental authority other than filings with the sec pursuant to the exchange act, or (b) violate, or cause a breach of or default under, or conflict with any contract, agreement or understanding, any law binding upon stockholder, except for such violations, breaches, defaults or conflicts which are not, individually or in the aggregate, reasonably likely to have a material adverse effect on stockholder&#8217;s ability to satisfy its obligations under this agreement. as of the date hereof, no proceedings are pending which, if adversely determined, will have a material adverse effect on stockholder&#8217;s ability to vote or dispose of any of the shares. &#160; 2.4 &#160;&#160;&#160; stockholder has adequate information .&#160;&#160;stockholder is a sophisticated seller with respect to the covered shares and has adequate information concerning the business and financial condition of the company to make an informed decision regarding the sale of the covered shares and has independently and without reliance upon either purchaser or parent and based on such information as stockholder has deemed appropriate, made its own analysis and decision to enter into this agreement. stockholder acknowledges that neither purchaser nor parent has made and neither makes any representation or warranty, whether express or implied, of any kind or character except as expressly set forth in this agreement. stockholder acknowledges that the agreements contained herein with respect to the covered shares held by stockholder are irrevocable (prior to the termination date). &#160; 2.5 &#160;&#160;&#160; no setoff . stockholder has no liability or obligation related to or in connection with the covered shares other than the obligations to parent and purchaser as set forth in this agreement. &#160; 3. &#160;&#160;&#160; representations and warranties of parent and purchaser .&#160;&#160;parent and purchaser hereby represent and warrant to stockholder, as of the date hereof that: &#160; 3.1 &#160;&#160;&#160; authorization .&#160;&#160;parent and purchaser have the legal capacity, power and authority to execute, deliver and perform all of their obligations under this agreement and to consummate the transactions contemplated hereby. parent and purchaser have duly and validly executed and delivered this agreement and this agreement is a legal, valid and binding agreement of each of parent and purchaser, enforceable against each of parent and purchaser in accordance with its terms, except to the extent enforceability may be limited by the effect of applicable bankruptcy, reorganization, insolvency, moratorium or other laws affecting the enforcement of creditors&#8217; rights generally and the effect of general principles of equity, regardless of whether such enforceability is considered in a proceeding at law or in equity. &#160; 3.2 &#160;&#160;&#160; no violation .&#160;&#160;neither the execution and delivery of this agreement nor the consummation of the transactions contemplated hereby will violate, or cause a breach of or default under, any contract or agreement, any statute or law, or any judgment, decree, order, regulation or rule of any governmental authority, except for such violations, breaches or defaults which are not reasonably likely to have a material adverse effect on either the parent&#8217;s or the purchaser&#8217;s ability to satisfy its obligations under this agreement. &#160; 4. &#160;&#160;&#160; survival of representations and warranties .&#160;&#160;none of the representations and warranties contained in this agreement shall survive the termination date. the respective representations and warranties of stockholder, parent and purchaser contained herein shall not be deemed waived or otherwise affected by any investigation made by the other party hereto. &#160; 5. &#160;&#160;&#160; specific performance .&#160;&#160;stockholder acknowledges that parent and purchaser will be irreparably harmed and that there will be no adequate remedy at law for a violation of any of the covenants or agreements of stockholder which are contained in this agreement. it is accordingly agreed that, in addition to any other remedies which may be available to parent and purchaser upon the breach by stockholder of such covenants and agreements, parent and purchaser shall have the right to obtain injunctive relief to restrain any breach or threatened breach of such covenants or agreements or otherwise to obtain specific performance of any of such covenants or agreements. &#160; 6. &#160;&#160;&#160; miscellaneous . &#160; 6.1 &#160;&#160;&#160; term .&#160;&#160;this agreement and all obligations hereunder shall terminate upon the earlier of (a) the effective time, (b) the date of any modification, waiver, change or amendment of the offer or the merger agreement executed after the date hereof that results in a (i) a decrease in the offer price or merger consideration (each as defined in the merger agreement on the date hereof) or (ii) a change in the form of consideration to be paid in the offer or in the form of merger consideration, and (c) the termination of the merger agreement in accordance with its terms (the earliest of (a), (b) and (c), the &#8220;termination&#160;&#160;date &#8221;). upon termination of this agreement, no party shall have any further obligations or liabilities under this agreement; provided , however , that (i) nothing set forth in this section 6.1 shall relieve any party from liability for any willful breach of this agreement prior to termination hereof, and (ii) the provisions of this article 6 shall survive any termination of this agreement. &#160; 6.2 &#160;&#160;&#160; capacity as a stockholder; fiduciary duties .&#160;&#160;notwithstanding anything in this agreement to the contrary: (a) stockholder makes no agreement or understanding herein in any capacity other than in stockholder&#8217;s capacity as a record holder and beneficial owner of all of the covered shares, and not in stockholder&#8217;s capacity as a director, officer or employee of the company or in stockholder&#8217;s capacity as a trustee or fiduciary of any employee benefit plan or trust, and (b) nothing herein will be construed to limit or affect any action or inaction by stockholder or any representative of stockholder, as applicable, serving on the company board or as an officer or fiduciary of the company or any employee benefit plan or trust, acting in such person&#8217;s capacity as a director, officer, trustee and/or fiduciary. &#160; 6.3 &#160;&#160;&#160; expenses . each of the parties hereto shall pay its own expenses incurred in connection with this agreement. each of the parties hereto warrants and covenants to the others that it will bear all claims for brokerage fees attributable to action taken by it. &#160; 6.4 &#160;&#160;&#160; binding effect .&#160;&#160;this agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective representatives and permitted successors and assigns. &#160; 6.5 &#160;&#160;&#160; entire agreement .&#160;&#160;this agreement constitutes the entire agreement of the parties with respect to the subject matter hereof and supersedes all prior agreements and understandings between the parties with respect to the subject matter hereof. this agreement may be amended only by a written instrument duly executed by the parties hereto. &#160; 6.6 &#160;&#160;&#160; headings .&#160;&#160;the headings contained in this agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this agreement. &#160; 6.7 &#160;&#160;&#160; assignment . without limitation to section 1.1 and subject to this section 6.7, this agreement shall be binding upon and inure to the benefit of the parties named herein and their respective successors and permitted assigns. no party may assign either this agreement or any of its rights, interests, or obligations hereunder without the prior written approval of the other parties; provided , however , that purchaser may freely assign, in its sole discretion and without the consent of any other party, any or all of its rights, interests and obligations hereunder to (a) parent, (b) parent and one or more direct or indirect wholly-owned subsidiaries of parent, (c) one or more direct or indirect wholly-owned subsidiaries of parent, or (d) any direct or indirect holder of five percent (5%) or more of the capital stock of parent or any subsidiary thereof (each an &#8220; assignee &#8221;). any such assignee may thereafter assign, in its sole discretion and without the consent of any other party, any or all of its rights, interests, and obligations hereunder to one or more additional assignees; provided , however , that (x) in no event will any assignment to an assignee cause a material delay or impair the ability of parent and purchaser to consummate the transactions and (y) in connection with any assignment to an assignee, parent and purchaser (and the assignor, if applicable) shall agree to remain liable for the performance by parent and purchaser (and such assignor, if applicable) of their obligation hereunder. &#160; 6.8 &#160;&#160;&#160; counterparts .&#160;&#160;this agreement may be executed in one or more counterparts (including by facsimile or by an electronic scan delivered by electronic mail), each of which shall be deemed an original, but all of which together shall constitute one and the same agreement and shall become effective when counterparts have been by signed by each of the parties hereto and delivered to the other parties, it being understood that all parties need not sign the same counterpart. &#160; 6.9 &#160;&#160;&#160; notices . any notice or other communication required or permitted hereunder shall be in writing and shall be deemed given when delivered in person, by overnight courier, by facsimile transmission (with receipt confirmed by telephone or by automatic transmission report) or by electronic mail, or two (2) business days after being sent by registered or certified mail (postage prepaid, return receipt requested), as follows: &#160; (a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;if to parent or purchaser, to: &#160; merck &amp; co., inc. one merck drive whitehouse station, new jersey 08889 attn:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;richard n. kender facsimile:&#160;&#160;(908) 735-1214 with a copy (which shall not constitute notice) to: fried, frank, harris, shriver &amp; jacobson llp one new york plaza new york, new york 10004 attn:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;david n. shine, esq. facsimile:&#160;&#160;(212) 859-4000 (b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;if to stockholder, to the address indicated on schedule i attached hereto. &#160; any party may by notice given in accordance with this section 6.9 to the other parties designate updated information for notices hereunder. &#160; 6.10 &#160;&#160;&#160; governing law .&#160;&#160;this agreement shall be governed by and construed and enforced in accordance with the laws of the state of delaware, without regard to any applicable principles of conflicts of laws. &#160; 6.11 &#160;&#160;&#160; enforceability .&#160;&#160;the invalidity or unenforceability of any provision or provisions of this agreement shall not affect the validity or enforceability of any other provision of this agreement, which shall remain in full force and effect. upon a determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto will negotiate in good faith to modify this agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the fullest extent possible and, absent agreement among the parties, a court is authorized to so modify this agreement. &#160; 6.12 &#160;&#160;&#160; further assurances .&#160;&#160;from time to time, at parent&#8217;s request and without further consideration, subject to the terms and conditions of this agreement, stockholder shall execute and deliver to parent such documents and take such action as parent may reasonably request in order to consummate more effectively the transactions contemplated hereby and to vest in parent good, valid and marketable title to the covered shares. &#160; 6.13 &#160;&#160;&#160; remedies not exclusive .&#160;&#160;all rights, powers and remedies provided under this agreement or otherwise available in respect hereof at law or in equity will be cumulative and not alternative, and the exercise of any thereof by either party will not preclude the simultaneous or later exercise of any other such right, power or remedy by such party. &#160; 6.14 &#160;&#160;&#160; waiver of jury trial .&#160;&#160;each party irrevocably and unconditionally waives any right to a trial by jury and agrees that any party may file a copy of this paragraph with any court as written evidence of the knowing, voluntary and bargained-for agreement among the parties irrevocably to waive its right to trial by jury in any litigation. &#160; 6.15 &#160;&#160;&#160; no agreement until executed .&#160;&#160;irrespective of negotiations among the parties or the exchanging of drafts of this agreement, this agreement shall not constitute or be deemed to evidence a contract, agreement, arrangement or understanding between the parties hereto unless and until (a) the company board has approved, for purposes of any applicable anti-takeover laws and regulations, and any applicable provision of the company&#8217;s certificate of incorporation, the possible acquisition of the shares by parent and purchaser pursuant to the merger agreement, (b) the merger agreement is executed by all parties thereto and (c) this agreement is executed by all parties hereto. &#160; [ the rest of this page has intentionally been left blank ] &#160; &#160; &#160; &#160; in witness whereof, parent, purchaser and stockholder have caused this agreement to be duly executed as of the day and year first above written. &#160; &#160; parent: &#160; &#160; &#160; &#160; &#160; merck &amp; co., inc. &#160; &#160; &#160; &#160; &#160; &#160; by: /s/&#160;richard n. kender &#160; &#160; &#160; name:&#160; richard n. kender &#160; &#160; &#160; title:&#160;&#160;&#160;&#160;senior vice president, business development &amp; corporate licensing &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; [ signature page to tender and support agreement ] &#160; &#160; &#160; &#160; &#160; &#160; &#160; purchaser: &#160; &#160; &#160; &#160; &#160; monarch transaction corp. &#160; &#160; &#160; &#160; &#160; &#160; by: /s/&#160;richard n. kender &#160; &#160; &#160; name:&#160; richard n. kender &#160; &#160; &#160; title:&#160;&#160;&#160;&#160;president &#160; &#160; &#160; &#160; [ signature page to tender and support agreement ] &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; stockholder: &#160; warburg pincus private equity ix, l.p.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; by:&#160; warburg pincus ix, llc, its general partner &#160; by:&#160; warburg pincus partners, llc its sole member &#160; by:&#160; warburg pincus &amp; co., its managing member &#160; &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; by: /s/ scott a. arenare&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; name:&#160;&#160;scott a. arenare &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;title:&#160;&#160;&#160; partner &#160; &#160; [ signature page to tender and support agreement ] &#160; &#160; &#160; &#160; schedule i &#160; name address shares &#160; &#160; &#160; warburg pincus private equity ix, l.p. attention: scott a. arenare, esq. 450 lexington avenue new york, ny 10017 facsimile:&#160;&#160;(212) 878-9351 22,907,488 &#160; &#160; &#160; &#160; 